Definium Therapeutics (DFTX) CLO Sullivan Sells $586K of Stock
Chief Legal Officer Mark Sullivan offloaded 13,008 shares of Definium Therapeutics as the stock trades near its 52-week high.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mark Sullivan, Chief Legal Officer at Definium Therapeutics, Inc. ($DFTX), sold 13,008 shares at an average price of $45.03, worth about $585,750.24, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $DFTX is down 1.3% after 1 week, down 4.8% after 1 month and down 28.3% to date (from the $44.79 close on Jun 25, 2026).
DFTX
Definium Therapeutics, Inc.
Key Points
- Definium Therapeutics, Inc. Chief Legal Officer Mark Sullivan sold 13,008 shares of DFTX stock on June 25, 2026, at a price of $45.03 per share.
- The transaction was valued at approximately $585,750 and was carried out under a pre-arranged trading plan.
- The stock changes hands near its 52-week high of $49.70 as the company heads toward its next earnings report on November 5, 2026.
Get $DFTX trade alerts by text
We text you when insiders, Congress or big funds trade $DFTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Definium Therapeutics, Inc.
Mark Sullivan, the Chief Legal Officer of Definium Therapeutics, Inc. (NasdaqGS: DFTX), sold 13,008 shares of the clinical-stage biopharmaceutical company on June 25, 2026. The shares were disposed of at an average price of $45.03, resulting in a total transaction value of $585,750.24. This planned sale was executed under a Rule 10b5-1 trading plan.
Broad Executive Selling Activity
The transaction coincided with similar planned sales by several other key executives at Definium Therapeutics on the same day. Chief Financial Officer Brandi Roberts sold 3,013 shares for about $135,675, while Chief Commercial Officer Matthew Wiley disposed of 2,867 shares valued at roughly $129,101. Chief Medical Officer Daniel Karlin also parted with 10,035 shares for a total of approximately $451,876. These routine sales followed earlier award grants to executives in late June.
DFTX Stock Performance and Range
Definium Therapeutics shares trade around $44.95, sitting close to the upper end of their 52-week range that spans from a low of $9.35 to a peak of $49.70. The stock trades well above its 50-day moving average of $42.28 and its 200-day moving average of $26.27. With a market capitalization of roughly $5.28 billion, the biotech firm is drawing strong interest from Wall Street ahead of its upcoming financial update.
Analysts Set New Price Targets
Analyst sentiment on the stock remains largely positive, supported by recent coverage updates from major financial firms. On October 9, 2026, JP Morgan initiated coverage on Definium Therapeutics with an Overweight rating and an $84.00 price target. Canaccord Genuity maintained a Buy rating on September 15 while raising its target to $78.00 from $64.00. Baird also kept an Outperform rating on September 15, lifting its target to $79.00 from $75.00. Overall, the consensus points to a strong buy rating with a mean target price of $71.65 across 17 analyst opinions.
Inside Definium Therapeutics
Definium Therapeutics develops novel product candidates focused on treating brain health disorders. Formerly known as Mind Medicine, the company operates out of New York and manages a clinical pipeline featuring lead candidates like DT120 for generalized anxiety disorder and major depressive disorder, alongside DT402 for autism spectrum disorder.
What to Watch at Definium Therapeutics, Inc.
Investors are looking ahead to the company's next earnings report, scheduled for release on November 5, 2026. Market participants will monitor further insider filing reports and clinical trial updates for the company's core drug candidates.
Related Filing Alerts
Source: Mark Sullivan's Form 4 filing on $DFTX (Jun 25, 2026). Find the original filing: DFTX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts